SNDX.OQ - Syndax Pharmaceuticals Inc
Guggenheim Securities LLC
SNDX - BUY - 4Q25 Recap: Revuforj Continues To Be Positioned As Menin Of Choice In R/R AML With Maintenance And NPM1 Driving Growth; IPF Study On-Track With Ph.2 TLR In 4Q26
公司
SNDX.OQ
日期
2026-02-26
分析师
Mr. Brad Canino
页数
7 页
需要登录
请登录后购买研报或生成音频内容。